Correlation of K19, EPCAM and α-fetoprotein (AFP) expression with clinicopathological features of surgical hepatocellular carcinoma (HCC) samples (resection and explant) obtained from 167 patients
| K19-positive HCCs | K19-negative HCCs | EPCAM-positive HCCs | EPCAM-negative HCCs | AFP-positive HCCs | AFP-negative HCCs | |
|---|---|---|---|---|---|---|
| Immunopositivity | 11.38% (19/167) | 88.62%(148/167) | 14.97% (25/167) | 85.03% (142/167) | 10.78% (18/167) | 89.22% (149/167) |
| Age (years) (mean) | 60.05 (ns) | 62.04 (ns) | 58.2 (ns) | 62.45 (ns) | 58.94 (ns) | 62.16 (ns) |
| Gender | ||||||
| Male | 63.16% (12/19; ns) | 74.32% (110/148; ns) | 68% (17/25; ns) | 63.94% (105/142; ns) | 77.78% (14/18; ns) | 72.48% (108/149; ns) |
| Female | 36.84% (7/19; ns) | 25.68% (38/148; ns) | 32% (8/25; ns) | 26.06% (37/142; ns) | 22.22% (4/18; ns) | 27.52% (41/149; ns) |
| Aetiology | ||||||
| HBV | 15.79% (3/19; ns) | 7.43% (11/148; ns) | 20% (5/25; ns) | 6.34% (9/142; ns) | 22.22% (4/18; ns) | 6.04% (9/149; ns) |
| HCV | 5.26% (1/19; ns) | 29.73% (44/148; ns) | 12% (3/25; ns) | 29.58% (42/142; ns) | 22.22% (4/18; ns) | 27.52% (41/149; ns) |
| HBV+HCV | 0% (0/19; ns) | 2.70% (4/148; ns) | 0% (0/25; ns) | 2.82% (4/142; ns) | 0% (0/18; ns) | 2.69% (4/149%; ns) |
| ALD | 10.52% (2/19; ns) | 16.22% (24; ns) | 16% (4/25;ns) | 15.49% (22/142; ns) | 16.67% (3/18; ns) | 15.44% (23/149; ns) |
| ALD+viral infection | 5.26% (1/19; ns) | 2.03% (3/148; ns) | 4% (1/25; ns) | 2.11% (3/142; ns) | 0% (0/18; ns) | 2.01% (3/149; ns) |
| Other | 36.84% (7/19; ns) | 27.70% (41/148; ns) | 36% (9/36; ns) | 27.46% (39/142; ns) | 27.78% (5/18; ns) | 30.2% (45/149; ns) |
| Unknown | 26.32% (5/19; ns) | 14.19% (21/148; ns) | 12% (3/25; ns) | 16.2% (23/142; ns) | 11.11% (2/18; ns) | 16.11% (24/149; ns) |
| Microvascular Invasion | 100% (19/19; p=0.0001) | 52.03% (77/148; ns) | 76% (19/25; p=0.0423) | 54.23% (77/142; ns) | 100% (18/18; p=0.0001) | 52.35% (78/149; ns) |
| Metastasis | 83.33% (10/12; p=0.0207) | 48.25% (55/114; ns) | 58.82% (10/17; ns) | 50.46% (55/109; ns) | 76.92% (10/13; ns) | 48.67% (55/113; ns) |
| Tumour size (cm. mean) | 6.77 (p=0.0077) | 4.5 | 5.27 (ns) | 4.72 | 4.92 (ns) | 4.79 |
| Differentiation grade | ||||||
| Well | 5.26% (1/19) | 45.27% (67/148) | 32% (8/25) | 42.25% (60/142) | 5.56% (1/18) | 44.97% (67/149) |
| Moderate | 36.84% (7/19) | 36.84% (54/148) | 28% (7/25) | 38.03% (54/142) | 38.89% (7/18) | 36.24% (54/149) |
| Poorly | 57.89% (11/19; p=0.0001) | 18.24% (27/148; ns) | 40% (10/25; ns) | 19.72% (28/142; ns) | 55.56% (10/18; p=0.0004) | 18.79% (28/149; ns) |
| Cirrhosis | ||||||
| No | 31.58% (6/19;ns) | 23.65% (35/148; ns) | 44% (11/25; ns) | 21.13% (30/142; ns) | 27.78% (5/18; ns) | 24.16% (36/149; ns) |
| Yes | 68.42% (13/19;ns) | 75% (111/148; ns) | 56% (14/25; ns) | 77.46 % (110/142; ns) | 72.22% (13/18. ns) | 74.5% (111/149; ns) |
| Unknown | 0% (0/19; ns) | 1.35% (2/148; ns) | 0% (0/25; ns) | 1.41% (2/142; ns) | 0% (0/18; ns) | 1.34% (2/149; ns) |
| Correlation of K19 expression with clinicopathological features of needle biospies obtained from 75 patients. | ||||||
| K19 positive HCCs | K19 negative HCCs | |||||
| Immunopositivity | 20% (15/75) | 80% (60/75) | ||||
| Age (years) (mean) | 63.93 (ns) | 64.13 (ns) | ||||
| Gender | ||||||
| Male | 66.67% (10/15; ns) | 73.33% (44/60; ns) | ||||
| Female | 33.33% (5/15; ns) | 26.67% (16/60; ns) | ||||
| Microvascular Invasion | 66.67% (10/15; p=0.007) | 21.67% (13/60; ns) | ||||
| Metastasis | 100% (5/5; p=0.0048) | 25% (3/12; ns) | ||||
| Differentiation grade | ||||||
| Well | 6.67% (1/15) | 30.67% (23/75) | ||||
| Moderate | 33.33% (5/15) | 40% (30/75) | ||||
| Poorly | 60% (9/15. p=0.0001) | 9.33% (7/75; ns) | ||||
| Cirrhosis | ||||||
| NO | 31.58% (6/19;ns) | 23.65% (35/148; ns) | ||||
| YES | 68.42% (13/19;ns) | 75% (111/148; ns) | ||||
| UNKNOWN | 0% (0/19; ns) | 1.35% (2/148; ns) | ||||
ALD, Alcoholic Liver Disease; HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; ns, not significant.
Bold indicates signifcant difference p<0.05.